"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data ...

The following is a summary of “Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma,” published in the March 2025 issue of International Journal of ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

4 Over time, treatments have become more effective at reducing the disease burden of multiple myeloma, but challenges remain. Even when there is no detectable disease, relapse can occur years ...

Dosage for multiple myeloma that has relapsed To treat relapsed multiple myeloma, the recommended dose of Velcade is 1.3 mg/m 2. But the dosing schedule is different. For this condition ...

“The GMMG ReLApsE trial does not support SHDCT/ASCT at relapse after prior frontline HDCT/ASCT regardless of TTP1,” authors of the study wrote. The study was supported by the Dietmar Hopp ...

Reference: Cook G, Ashcroft AJ, Senior E, et al. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...